ĐÁNH GIÁ KHẢ NĂNG LY GIẢI CÁC DÒNG TẾ BÀO UNG THƯ CD19(+) CỦA LIỆU PHÁP ĐIỀU TRỊ KẾT HỢP TẾ BÀO CAR-T VỚI KHÁNG THỂ ĐƠN DÒNG ỨC CHẾ PD-1 TRÊN THỰC NGHIỆM

Abstract

Objective: Evaluating the lytic efficacy of combination therapy of CD19-targeted CAR-T cells with anti-PD-1 monoclonal antibody on CD19(+) cancer cell lines in vitro. Methods: This is an experimentally prospective study. Daudi, Raji (CD19+) or K562 (CD19-) cancer cells (target, CFSE stained) were co-cultured with PBMC, CAR-T cells (effector) at a ratio of 1:2, 1:5, 1: 10. Anti-PD-1 monoclonal antibody was used at concentration of 20µg/mL. After 6 hours of co-culture, cells were stained with 7AAD and analyzed on a flowcytometry system to evaluate the ratio of live and dead cells. Results: CAR-T cells  and CAR-T cells combined with anti-PD-1 monoclonal antibody had lytic effect on CD19+ cancer cells. The CAR-T+ anti-PD-1 combination treatment did not increase lysis rate on Daudi cells but increased lysis rate 1.82 times on Raji cell when the Raji/CAR-T ratio= 1:10 (p <0.001). The effectiveness of CAR-T or CAR-T combined with anti-PD-1 were not much different compared to PBMC on cancer cells with CD19(-). Conclusion: CAR-T cells and CAR-T cells combined with anti-PD-1 monoclonal antibody had lytic effect on CD19+ cancer cells. The combination therapy of CAR-T cells and anti-PD-1 monoclonal antibody increased lysis rate 1.82 times on Raji cells